Background and Hypotheses: Human starch digestion is a multienzyme process involving 6 different enzymes: salivary and pancreatic a-amylase; sucrase and isomaltase (from sucrose-isomaltase [SI]), and maltase and glucoamylase (from maltase-glucoamylase [MGAM]). Together these enzymes cleave starch to smaller molecules ultimately resulting in the absorbable monosaccharide glucose. Approximately 80% of all mucosal maltase activity is accounted for by SI and the reminder by MGAM. Clinical studies suggest that starch may be poorly digested in those with congenital sucrase-isomaltase deficiency (CSID). Poor starch digestion occurs in individuals with CSID and can be documented using a noninvasive
C ongenital-sucrase isomaltase deficiency (CSID) is an autosomal recessive intestinal disorder produced by mutations on the intestinal brush border enzyme complex sucrase-isomaltase (SI) (1) (2) (3) . CSID patients frequently experience symptoms such as chronic osmotic diarrhea, abdominal pain, and bloating. CSID symptoms rarely lead to failure to thrive. The severity of the resultant symptoms is related to multiple factors, such as the amount of sucrase activity, the amount of sucrose ingested, the rate of gastric emptying, colonic microbial diversity, and fermentative and absorptive capacity of the colon (4) .
CSID occurs in approximately 0.2% of individuals of European descent, and in >5% of indigenous Greenlanders (5) . The SI mutation, c.273_274delAG, has been found to be responsible for the high prevalence of congenital sucrase-isomaltase deficiency among Inuit people (6) . To date, >40 mutations to the SI gene have been identified that are variably expressed (7) . Two percent to 9% of Americans of European descent are heterozygous carriers, with normal small intestinal histology and sucrase/maltase activity levels below the lower limits for the general population (6, 7) . The pattern of inheritance of CSID is either based on single mutations on both alleles (homozygous pattern) or caused by compound heterozygosity, thus suggesting that CSID may be more common than previously thought (2) . Seven different CSID phenotypes have been described, in which SI enzyme activities range from reduction of sucrase activity to total absence, and to variable absence of isomaltase and normal small intestinal histology (2) .
What Is Known
Children with congenital sucrase isomaltase deficiency have both sucrase and maltase deficiencies. Identifying children with congenital sucrase isomaltase deficiency with starch malabsorption is currently challenging. Breath testing may provide a noninvasive method to determine the potential for starch malabsorption.
What Is New
In children with congenital sucrase isomaltase deficiency, 13 C-labeled-starch breath testing provides valuable information re: starch absorption. Sucrase deficiency in children with congenital sucrase isomaltase deficiency correlates well with decreased glucogenesis from starches.
Reduced maltase activity occurs in all CSID patients, because both subunits in the SI complex contribute to total mucosal maltase activity (8) , which includes downstream a-amylasederived soluble dextrin hydrolysates. This is consistent with previous clinical reviews that report some CSID patients may have starch maldigestion (9) . Confirmation of starch maldigestion at the mucosal level is difficult, because there is no specific substrate for enzyme assays, and SI and MGAM contribute to both maltase and glucoamylase assay activities.
Stable isotope-labeled breath tests (BTs) provide a noninvasive method for evaluation of starch digestion (10) (11) (12) (13) (14) . Previous investigations have shown that the integration of the multistep starch digestion to the glucose pathway can be mapped both anatomically and physiologically by 13 C-substrates and H 2 production (11) (12) (13) (14) . Because the chemical structure of the starches affects the digestibility of the 13 C-substrate (12), we have chosen to use a universally labeled algal starch as the standard tracer to assess aamylase, SI and MGAM activity and eliminate the cramping symptoms commonly associated with large starch loads in H 2 BTs. When compared with maize starch (Supplemental Figure 1 , Supplemental Digital Content 1, http://links.lww.com/MPG/B207), amylase treatment of algal starch produces 83% less maltotriose, thus a reduced ''braking'' effect (1), and longer branch chains (20) , both features that specifically enhance MGAM activity.
This study was undertaken to prove our hypothesis, that sucrase deficiency results in decreased glucogenesis from starches and points to an unaddressed pathophysiologic concern.
METHODS
We used a 13 C-BT to determine starch digestion in a group of CSID patients; 13 C-labeled starch was used as the BT substrate. This group of patients was previously studied with a 13 C-sucrose BT showing correlation with mucosal sucrase activities as previously reported (15, 16) . Adults and children have different rates of glucose oxidation; thus, we used a separate 13 C-glucose BT to normalize individual test substrate oxidation, called coefficient of glucose oxidation (% CGO), to permit intergroup and between group comparisons to be performed. 13 C-Starch BTs were performed on separate days to avoid erroneous attribution of recovered isotopic tracer indicative of the target or the reference substrate. Of note, 13 C-glucose, derived from hydrolyzed 13 C-starch theoretically undergoes the same oxidative fate as 13 C-glucose, presented in monomer form, to the intestinal mucosal. This approach effectively eliminates the need to adjust oxidative outcome data using estimated carbon dioxide production rates or onerous calorimetry procedures. The control subjects were patients with normal mucosal enzyme activities (M AE 1 SD); their histology had been biopsied for clinical indications.
CLINICAL
The study was approved by the Baylor College of Medicine Institutional Review Board. Informed consent was obtained from the parents of study participants; a total of 17 patients were studied under protocols, H-1320 and H-10239. Eleven patients with CSID, diagnosed by duodenal enzyme activity, with normal histology, were included in the study (6 females, 5 males; ages from 11 months to 15 years).
Six control patients underwent endoscopy and biopsy at the Nutrition and Gastroenterology Service at Texas Children's Hospital (TCH) for symptoms of dyspepsia, abdominal pain, or chronic diarrhea (1 female, 5 males; ages 8 months to 10 years). All had normal disaccharidase levels according to results using the Dahlqvist method (17); all had normal histology. Six CSID family members were studied by administering a BT, but without biopsy assays.
CHARACTERIZATION OF ALGAL STARCH SUBSTRATE
Normal maize starch and UL 13 C-algal starch samples were dissolved in deionized water (10 mg/mL, w/v), and boiled for 20 minutes with stirring. Starch solutions were combined with 100 mM sodium acetate buffer (100 mL, pH 5.0). The mixture was incubated with pullulanase (0.72 units; Megazyme, Wicklow, Ireland) at 408C for 48 hours, resulting in the hydrolysis of the a-1,6 linkages. Debranched linear chain-length distributions of the enzyme-treated starches were measured and molecular weight was determined using multi-angle laser-light scattering (MALS, Dawn Heleos-II; Wyatt Tech. Corp, Santa Barbara, CA). The collected data were analyzed using a Berry plot for curve fitting with Astra software version V (Wyatt Tech. Corp) (19).
CO 2 -BREATH TESTS
The 13 CO 2 breath tests were administered for 2 days for the control groups and for 3 days for the CSID group at the General Clinical Research Center at TCH (the third day was a test of response to oral Sucraid enzyme replacement). After overnight fasting, a 2.5 L-reference breath sample was collected for comparison with the timed breath samples. Then 20 mg uniformly labeled 13 C-glucose (Isotec [Div. of Sigma-Aldrich], Miamisburg, OH) was given using 10 g-unlabeled maltodextrins, as a carrier, dissolved in water to a total volume of 100 mL (Polycose; Ross Division of Abbot Laboratories, Columbus, OH). Beginning 15 minutes after the 13 C-glucose load, breath samples (0.25 L) were collected every 15 minutes for 120 minutes. After finishing the BT, the subject was fed and released from the General Clinical Research Center. On the second day, the procedure was the same, but 13 C-sucrose was used. For the 13 C-starch BT, a uniformly labeled 13 C-algal starch (Isotec) was used. After each 13 C-labeled substrate load was administered, breath collections and measurements of breath 13 CO 2 enrichments were performed using a 13 CO 2 infrared spectrophotometer (POCone; Otsuka Electronics, Tokyo, Japan). The BT results were recorded as total breath CO 2 concentration expressed as delta over baseline of reference PeeDee Belamite 13 C-standard (DOB) for glucose-DOB 13 CO 2 , sucrose-DOB 13 CO 2 , or starch-DOB 13 CO 2 . The sucrose and starch 13 CO 2 concentrations were expressed as a ratio to the 13 C-glucose concentrations, to normalize for the metabolism of age modification: % CGO (15, 18) . The BT results between 30 and 90 minutes were averaged to produce a simplified equivalent of approximate ''area under curve'' calculations.
RESULTS
The debranched uniformly labeled 13 C-algal-starch, produced by a proprietary culture of edible cyanobacteria grown within a 13 CO 2 environment, was compared with debranched normal maize starch (Supplemental Figure 1 , Supplemental Digital Content 1, http://links.lww.com/MPG/B207). Compared with maize starch, the 13 C-algal-starch spectrum reveals a 6-fold reduction of maltotriose, signifying a reduced maltotriose braking effect on glucoamylase activity (1) and a shift to longer linear oligomers that favor glucoamylase activity (20) .
The 13 CO 2 test substrate/ 13 CO glucose (% CGO) was calculated for breath enrichments to adjust for individual glucose metabolic differences in our study subjects. No clinical symptoms or adverse events were observed from any of the 13 C-substrates administered during the study. The 13 CO 2 % CGO values from 30 to 90 minutes were averaged (Table 1) . Controls defined a 13 C-starch benchmark lower level as mean À1 SD (91.1 AE 25.7 ¼ lower level 65% CGO). All patients with CSID had deficient 13 C-labeled starch digestion (19.4 AE 10.6% CGO). The CSID group had starch digestion and oxidation below the levels of the control group (P ¼ 0.001). There was a strong correlation between 13 C-starch and 13 C-sucrose BT-values in the combined groups (Fig. 1, R 2 ¼ 71%) and a correlation between the 13 C-starch BT values and the measured duodenal sucrase activity ( 
DISCUSSION
Given the severity of clinical symptoms, which may occur in children with CSID, identifying the dietary substrates that may be malabsorbed is important. Using a novel breath testing protocol with 13 C-starch we found that children with CSID who have impaired sucrase activity (and previously documented sucrose malabsorption) also have starch malabsorption. This technique may pave the way toward further noninvasive testing of mucosal starch capacity in other clinical populations. We also identified in children with CSID that starch malabsorption correlated well with the measures of sucrose malabsorption. If our findings are further supported, children with CSID who have severely affected sucrase activity are likely to benefit not only from sucrose avoidance but starch avoidance as well.
CSID patients have low to a total deficiency of duodenal assay sucrase, although some retain residual isomaltase activity at a variable level. The mean importance is that in CSID, the symptoms are attributed to sucrose intolerance leading to aforementioned symptoms, but the importance of starch maldigestion has not been generally appreciated. The reason for this may be as simple the avoidance of discussion of what could not be easily measured or assessed. As such, the 13 C-glucose-paired 13 C-starch BT addresses this diagnostic void. In addition, some patients present with fermentative diarrhea caused by low starch digestion; a condition that occurs to a lesser degree, however, than that caused by ingestion of sucrose. This observation was made first by Auricchio et al in 1963 (9) . We have demonstrated in our study of CSID patients that all had low 13 C-starch % CGO for starch digestion. Our test hypothesis that sucrase deficiency results in decreased glucogenesis from starches was confirmed. Although first reported in animal studies (21, 22) , our findings provide clinical confirmation of the leading role of small intestinal sucrase in normal human starch. Given that Sucraid is a specific sacrosidase used for treating CSID that is without starch digesting activity, further research is suggested to test other oral glucosidase enzymes that can correct their reduced starch digestion. 13 C-labeled starch vs 13 C-labeled sucrose breath tests (BTs). The two BT substrates were tested on different days. The breath 13 CO 2 enrichments between 30 and 90 minutes following substrate ingestion were averaged and expressed in ratio to 13 C-glucose (expressed as % CGO) tested on a third day. The linear equation fit is 13 C-Starch ¼ 6.53 þ 0.564 13 C-Sucrose (R 2 ¼ 71%). Note that the 13 C-starch BT response is driven by the 13 C-sucrose response suggesting that sucrose digestion accounts for about 70% of starch digestion. C-starch BT is described sucrase activity. Note that the y intercept is positive at almost 20 SA, suggesting that sucrase is not the only enzyme activity participating in starch glucogenesis.
We envision a potentially broader role for a simplified noninvasive 13 C-starch BT as quantitative clinical measurements throughout recovery from secondary small intestinal mucosa diseases such as malnutrition, environmental enteropathy, celiac disease, Crohn disease, ulcerative colitis, chemotherapy mucositis, or transplant rejection.
